{
    "clinical_study": {
        "@rank": "35144", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "REGN1033 (SAR391786)"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo + exercise regimen"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "REGN1033 (SAR391786) + exercise regimen"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to assess the safety and bioeffect of REGN1033 (SAR391786) in healthy\n      volunteers."
        }, 
        "brief_title": "Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Males and postmenopausal females aged 60 years and older with no significant health\n             issues or clinically significant abnormal laboratory values.\n\n          2. Low activity lifestyle\n\n          3. Diet and exercise adherence\n\n        Exclusion Criteria:\n\n          1. Significant concomitant illness such as, but not limited to cardiac, renal,\n             rheumatologic, gastrointestinal, hematological, skeletal/muscular, neurologic,\n             psychiatric, endocrine, metabolic or immunological disease.\n\n          2. Participation in any clinical trial within 6 months prior to screening.\n\n          3. Hospitalization, immobilization, or major surgical procedure requiring general\n             anesthesia within 6 months prior to screening, or any planned surgical procedures\n             during the study period.\n\n          4. Limb amputation (except for toes) and/or any fracture within 6 months.\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial and not all inclusion/ exclusion\n        criteria are listed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910220", 
            "org_study_id": "R1033-HV-1223"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 2", 
                    "Group 4"
                ], 
                "intervention_name": "REGN1033 (SAR391786)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 3"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "clinicaltrials@regeneron.com", 
            "last_name": "Clinical Trials Administrator"
        }, 
        "overall_official": {
            "affiliation": "Regeneron Pharmaceuticals", 
            "last_name": "Clinical Trial Management", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is percent change in total lean mass at week 12 (day 85)", 
            "measure": "Percent change in total lean mass", 
            "safety_issue": "No", 
            "time_frame": "At week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910220"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of treatment-emergent adverse events (TEAEs) from day 1 (baseline) to day 141 (end of study)", 
                "measure": "Number of TEAEs", 
                "safety_issue": "Yes", 
                "time_frame": "day 1 to day 141"
            }, 
            {
                "description": "Appendicular lean mass by DXA (dual energy X-ray absorptiometry) at week 12", 
                "measure": "Appendicular lean mass by DXA", 
                "safety_issue": "No", 
                "time_frame": "At week 12"
            }
        ], 
        "source": "Regeneron Pharmaceuticals", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Regeneron Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}